Evidence map›Paper›PMID 41441785›Full record

ArticleChemistry (Weinheim an der Bergstrasse, Germany)2026

Development of tCAP(N3): Affinity Peptide-Aided, pH-Triggered Strategy for Site-Specific Native IgG Modification.

Hiroko Kawakami, Abdur Rafique, Shugo Tsuda, Asaki Nagashima, Yukie Nohara, Naoki Dozono, Ken Sakamoto, Shun Masuda, Masato Kiyoshi, Hiroko Shibata and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Chemistry (Weinheim an der Bergstrasse, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Hiroko KawakamiGraduate School of Science and Engineering, Kagoshima University, Kagoshima, Japan.
Abdur RafiqueGraduate School of Science and Engineering, Kagoshima University, Kagoshima, Japan.
Shugo TsudaPeptide Institute, Inc., Osaka, Japan.
Asaki NagashimaGraduate School of Science and Engineering, Kagoshima University, Kagoshima, Japan.
Yukie NoharaPeptide Institute, Inc., Osaka, Japan.
Naoki DozonoGraduate School of Science and Engineering, Kagoshima University, Kagoshima, Japan.
Ken SakamotoPeptide Institute, Inc., Osaka, Japan.
Shun MasudaPeptide Institute, Inc., Osaka, Japan.
Masato KiyoshiDivision of Biological Chemistry and Biologicals, National Institute of Health Sciences, Kanagawa, Japan.
Hiroko ShibataDivision of Biological Chemistry and Biologicals, National Institute of Health Sciences, Kanagawa, Japan.
Akiko Ishii-WatabeDivision of Biological Chemistry and Biologicals, National Institute of Health Sciences, Kanagawa, Japan.
Taku YoshiyaPeptide Institute, Inc., Osaka, Japan.
Yuji ItoGraduate School of Science and Engineering, Kagoshima University, Kagoshima, Japan.ORCID https://orcid.org/0000-0002-5239-5070

Funding

the Japan Agency for Medical Research and Development (AMED)
6 · The paper itself

Abstract

Direct modification of native antibodies with affinity peptides remains a significant challenge, primarily because the affinity peptide often stays bound to the antibody and blocks its interaction with key receptors. In this study, we developed tCAP(N3), a novel traceless chemical conjugation method that employs an affinity peptide. tCAP(N3) can be stored for over a year at refrigerated temperature, as it contains an active ester precursor that can be spontaneously activated under neutral conditions. When tCAP(N3) was mixed with a target native IgG, Ac-Lys(N

Indexed as

Immunoglobulin GPeptidesHumansHydrogen-Ion ConcentrationReceptors, FcImmunoglobulin GPeptidesReceptors, Fcantibodyantibody drug ratiocancerpayloadstoxic effects

Identifiers

PMID41441785
PMCPMC12887602

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.